Purchase Order 75N91026P00007
Award Date 3/1/26
Potential Completion Date 2/28/27
Potential Value $20K
Federal Agency
Ultimate Awardee
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not listed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
San Jose, CA 95131, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Service Contract Inventory
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- Becton, Dickinson and Company (BD), through its BDB Division operating as BD Biosciences, was awarded a Firm Fixed Price contract by the National Cancer Institute (NCI) on May 3, 2017, with a ceiling value of $17,928.00. This contract was executed as a Blanket Purchase Agreement (BPA) call without small business set-aside designation, reflecting BD's competitive standing as a large, established medical technology manufacturer. The work was to be performed in Bethesda, Maryland, with an...
- Becton, Dickinson and Company (BD), through its BD Biosciences division, was awarded a $9,126 fixed-price contract with economic price adjustment by the National Cancer Institute for maintenance services on a FACSCalibur 4 CLR flow cytometry instrument (Serial #E1806, Customer Material #343023). The contract represents a Call under a Blanket Purchase Agreement vehicle and covers the period from January 1, 2015 through December 31, 2015, with performance at the National Cancer Institute...
- Becton, Dickinson and Company, through its BD Biosciences division, was awarded a delivery order maintenance agreement by the National Cancer Institute valued at $154,840.80 under the Multiple Award Schedule on February 1, 2023. This firm fixed-price contract, with an ultimate completion date of January 31, 2028, provides maintenance services for specialized laboratory instrumentation at the National Cancer Institute's Bethesda, Maryland facility. The award is part of BD's broader portfolio of...
- The National Cancer Institute awarded a $700,000 firm fixed-price purchase order to Becton, Dickinson and Company (operating as BD Biosciences) on September 16, 2024, for equipment lease, maintenance services, and consumables supporting the NCI Flow Cytometry Unit in Bethesda, Maryland. This non-compete procurement fulfills the Laboratory of Pathology Flow Cytometry Laboratory's need for BD-owned flow cytometry instruments with warranty and preventive maintenance coverage, along with...
- Becton, Dickinson and Company, through its BDB Division operating as BD Biosciences, received a $15.7K firm fixed-price Blanket Purchase Agreement (BPA) call award from the National Cancer Institute (NCI) on August 21, 2014, with completion targeted for March 31, 2015. This contract represents a call against an existing BPA vehicle and does not include a small business set-aside designation. The work will be performed in Bethesda, Maryland, and BD Biosciences will provide specialized...
- This federal contract award was made by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to Becton, Dickinson and Company's IDS division, operating as BD Diagnostic Systems. The $698,027.48 firm fixed price purchase order was awarded on August 29, 2018 to provide a BD Biosciences FACSymphony, or equal, fluorescent analytical flow cytometer. This equipment is being procured to support the National Cancer Institute's research programs. The...
- This is a $105,926.44 firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health, to Becton, Dickinson and Company (BD) under the FSS-66 Scientific Equipment and Services federal supply schedule. The contract is for a SERVICE AGREEMENT with a period of performance through February 28, 2025. This delivery order is not a set-aside contract. BD is a global medical technology company that provides specialized equipment,...
- Becton, Dickinson and Company (BD), operating through its BDB Division as BD Biosciences, was awarded a purchase order valued at $24,924.63 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMSD), a component of the National Institutes of Health. The contract, awarded on December 30, 2025, covers a period of performance from December 29, 2025, through July 16, 2026, with an ultimate completion date of July 17, 2026. The award encompasses service contracts for...
- This is a federal contract award to Becton, Dickinson and Company (BD) by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), for maintenance services on government-owned Becton Dickinson instrumentation. The $141,480.00 firm fixed-price purchase order supports the work of the NCI's Center for Cancer Research, Experimental Immunology Branch. The contract has no set-aside designation and was awarded on February 1, 2017, with a completion date of January...
- The National Cancer Institute awarded a Blanket Purchase Agreement (BPA) call to Becton, Dickinson and Company (BD), through its BD Biosciences division, for a one-year maintenance agreement on a FACSCalibur 4 CLR/Sort flow cytometry instrument (Serial #E4950). The contract, valued at $13,235.40 with a fixed-price structure including economic price adjustment provisions, was awarded on February 7, 2015, for performance at NCI facilities in Bethesda, Maryland. This call represents maintenance and...